Companion animals have become family, increasing the demand for more sophisticated and effective therapies. TriviumVet are developing novel treatments for previously unmet needs in our cats and dogs.
Waterford, Ireland-based TriviumVet is making waves in veterinary medicine with its breakthroughs in companion animal healthcare. Focused on addressing unmet clinical needs, the company is pioneering treatments for chronic illnesses in pets – an area where effective solutions have long been lacking.
Innovation meets purpose
Founded by visionaries Louise Grubb and Tom Brennan, TriviumVet’s portfolio of products works to address chronic diseases where there are little or no therapeutic options for clinicians and owners. The company has since developed an impressive pipeline of first-to-market veterinary treatments and new animal drugs, targeting conditions like feline hypertrophic cardiomyopathy (HCM), canine neuropathic pain, gastric ulcers in dogs, and chronic kidney disease in pets.
TriviumVet’s flagship product for cats represents a monumental breakthrough. This patented, delayed-release formulation of sirolimus offers the first-ever option for HCM, a debilitating disease affecting up to 15% of cats. The company is on the verge of securing regulatory approval for the product in the United States, empowering veterinarians to intervene earlier, potentially transforming the lives of countless feline patients.
A unique approach to veterinary medicine development
What sets TriviumVet apart is its innovative approach:
- Focus on unmet needs: The company targets diseases lacking effective treatments, ensuring their efforts address the most pressing challenges in veterinary healthcare.
- Adapting human medical advances: By leveraging cutting-edge technologies from human medicine, TriviumVet brings novel solutions to the veterinary sector.
- Species-specific formulations: Therapeutics are tailored for individual species, ensuring optimal efficacy and safety.
- Holistic health solutions: Beyond treating specific conditions, TriviumVet develops therapies that enhance pets’ overall quality of life, addressing age-related decline and chronic diseases.
These differentiators not only fill gaps in traditional veterinary care but also set a new standard for innovation in animal health.
Global vision, local roots
Under the leadership of CEO Louise Grubb, TriviumVet combines a global perspective with local dedication. TriviumVet’s ability to take products from concept to market is supported by a robust internal team and a network of external experts, including Key Opinion Leaders, Contract Research Organisations, and Contract Manufacturing Organisations. While manufacturing is outsourced, quality and development remain firmly under TriviumVet’s control.
This collaborative model ensures not only rigorous development processes but also a strong endorsement from veterinary professionals, positioning the company’s products for widespread adoption upon launch.
A promising future for veterinary medicine
With its innovative drug delivery systems, rigorous R&D processes, and dedication to addressing unmet needs, TriviumVet is poised to revolutionise veterinary medicine. Grubb said: “Pets are increasingly seen as family members, and this shift drives demand for advanced healthcare solutions.”
TriviumVet is at the forefront of this transformation, delivering therapies that meet the rising expectations of pet owners. Their efforts promise to not only improve the health and longevity of pets but also provide veterinarians with the tools they need to make meaningful differences in their patients’ lives.
TriviumVet’s journey is a testament to the power of innovation and purpose-driven leadership. As they continue to break new ground, the company is solidifying its position as a leader in companion animal healthcare – a milestone that deserves recognition and celebration.
Please note, this article will also appear in the 21st edition of our quarterly publication.
